Cytori Therapeutics Inc (CYTX) Reaches New 1-Year Low at $0.47

Cytori Therapeutics Inc (NASDAQ:CYTX) shares hit a new 52-week low on Monday . The company traded as low as $0.47 and last traded at $0.48, with a volume of 5,290,085 shares trading hands. The stock had previously closed at $1.11.

CYTX has been the topic of a number of research reports. B. Riley restated a “buy” rating and issued a $2.30 price objective on shares of Cytori Therapeutics in a report on Wednesday, May 10th. Zacks Investment Research upgraded Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Tuesday, July 11th. Maxim Group set a $10.00 price objective on Cytori Therapeutics and gave the company a “buy” rating in a report on Wednesday, May 31st. Finally, ValuEngine lowered Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st.

The firm’s 50-day moving average price is $0.69 and its 200 day moving average price is $1.16. The stock’s market cap is $11.20 million.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.02. The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.23 million. Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. The business’s revenue for the quarter was down 18.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.43) earnings per share. Equities research analysts forecast that Cytori Therapeutics Inc will post ($0.60) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Perkins Capital Management Inc. increased its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 10.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 439,679 shares of the biotechnology company’s stock after buying an additional 40,839 shares during the period. Perkins Capital Management Inc. owned 1.87% of Cytori Therapeutics worth $703,000 as of its most recent filing with the SEC. 10.01% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Cytori Therapeutics Inc (CYTX) Reaches New 1-Year Low at $0.47” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

What are top analysts saying about Cytori Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytori Therapeutics Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit